HSA
KITE

Hussman Strategic Advisors’s Kite Pharma, Inc. KITE Stock Holding History

Hussman Strategic Advisors’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-35,000
Closed -$2.75M – 216
2017
Q1 		$2.75M Buy
+35,000
New +$2.16M 0.61% 80

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hussman Strategic Advisors's KITE Position: Q2 2017 in Review

Hussman Strategic Advisors sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 35,000 shares — an estimated $2.75M sold.

Hussman Strategic Advisors first reported a position in KITE in Q1 2017 and held it in 1 quarter. The position peaked at $2.75M in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

  • Hussman Strategic Advisors reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Hussman Strategic Advisors sold 35,000 Kite Pharma, Inc. shares in Q2 2017, an estimated $2.75M.
  • Hussman Strategic Advisors first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 1 quarter.
  • Hussman Strategic Advisors's Kite Pharma, Inc. position peaked at $2.75M in Q1 2017.
  • 220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on Hussman Strategic Advisors's 13F filing for Q2 2017, filed 1 Aug 2017.